James George Chopas News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from James george chopas. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In James George Chopas Today - Breaking & Trending Today

Wedbush Weighs in on Apellis Pharmaceuticals, Inc.'s FY2025 Earnings (NASDAQ:APLS)

Apellis Pharmaceuticals, Inc. (NASDAQ:APLS – Free Report) – Investment analysts at Wedbush dropped their FY2025 EPS estimates for Apellis Pharmaceuticals in a report released on Wednesday, April 17th. Wedbush analyst L. Chico now expects that the company will earn $2.23 per share for the year, down from their prior estimate of $2.24. Wedbush currently has […] ....

United States , Adamj Townsend , Robertw Baird , James George Chopas , Securities Exchange Commission , Hedge Funds Weigh In On Apellis Pharmaceuticals , Apellis Pharmaceuticals Inc , Apellis Pharmaceuticals Stock Performance , Charles Schwab Investment Management Inc , News Ratings For Apellis Pharmaceuticals Daily , Goldman Sachs Group , Profund Advisors , Apellis Pharmaceuticals , American Investors Co , Wynnefield Capital Inc , Jefferies Financial Group , Free Report , Apellis Pharmaceutical , Get Free Report , Financial Group , George Chopas , Exchange Commission , American Investors , Schwab Investment Management , Apellis Pharmaceuticals Daily ,

Apellis Pharmaceuticals (NASDAQ:APLS) Stock Price Up 2.3%

Apellis Pharmaceuticals (NASDAQ:APLS) Stock Price Up 2.3%
themarketsdaily.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from themarketsdaily.com Daily Mail and Mail on Sunday newspapers.

Robertw Baird , James George Chopas , Davido Watson , Vanguard Group Inc , Jefferies Financial Group , Insider Activity At Apellis Pharmaceuticals , Sierra Summit Advisors , Institutional Investors Weigh In On Apellis Pharmaceuticals , Apellis Pharmaceuticals Price Performance , Apellis Pharmaceuticals Inc , Needham Company , Pricet Rowe Associates Inc , News Ratings For Apellis Pharmaceuticals Daily , Eventide Asset Management , Apellis Pharmaceuticals , Securities Exchange Commission , Jpmorgan Chase Co , Get Free Report , Financial Group , George Chopas , Exchange Commission , General Counsel David , Summit Advisors , Asset Management , Pricet Rowe Associates , Apellis Pharmaceuticals Daily ,

JPMorgan Chase & Co. Increases Apellis Pharmaceuticals (NASDAQ:APLS) Price Target to $79.00

Apellis Pharmaceuticals (NASDAQ:APLS – Free Report) had its target price lifted by JPMorgan Chase & Co. from $78.00 to $79.00 in a research note published on Wednesday morning, Benzinga reports. JPMorgan Chase & Co. currently has an overweight rating on the stock. A number of other brokerages also recently issued reports on APLS. Robert W. […] ....

Robertw Baird , James George Chopas , Adamj Townsend , Apellis Pharmaceuticals , Jefferies Financial Group , Needham Company , First Horizon Advisors Inc , Stephens Consulting , Jpmorgan Chase Co , Analyst Recommendations For Apellis Pharmaceuticals , Us Bancorp , Covestor Ltd , Apellis Pharmaceuticals Inc , Apellis Pharmaceuticals Stock Down , Apellis Pharmaceuticals Company Profile , Institutional Investors Weigh In On Apellis Pharmaceuticals , Wealth Management Inc , Securities Exchange Commission , News Ratings For Apellis Pharmaceuticals Daily , Free Report , Financial Group , Moderate Buy , Pharmaceuticals Stock Down , Get Free Report , George Chopas , Exchange Commission ,

Apellis Pharmaceuticals (NASDAQ:APLS) Releases Earnings Results, Meets Estimates

Apellis Pharmaceuticals (NASDAQ:APLS – Get Free Report) issued its earnings results on Tuesday. The company reported ($0.73) earnings per share for the quarter, hitting analysts’ consensus estimates of ($0.73), Briefing.com reports. The business had revenue of $146.38 million during the quarter, compared to the consensus estimate of $143.34 million. Apellis Pharmaceuticals had a negative return […] ....

United States , Cedric Francois , James George Chopas , Jefferies Financial Group , Securities Exchange Commission , Needham Company , Us Bancorp , Hedge Funds Weigh In On Apellis Pharmaceuticals , Goldman Sachs Group , Sigma Securities , Apellis Pharmaceuticals , Apellis Pharmaceuticals Price Performance , Apellis Pharmaceuticals Inc , Nelson Van Denburg Campbell Wealth Management Group , News Ratings For Apellis Pharmaceuticals Daily , Earnings History For Apellis Pharmaceuticals , Advisor Group Holdings Inc , Apellis Pharmaceuticals Company Profile , Insider Activity At Apellis Pharmaceuticals , Get Free Report , Financial Group , George Chopas , Exchange Commission , Group Holdings , Van Denburg , Campbell Wealth Management Group ,

Apellis Pharmaceuticals (NASDAQ:APLS) Earns "Buy" Rating from HC Wainwright

Apellis Pharmaceuticals (NASDAQ:APLS – Get Free Report)‘s stock had its “buy” rating reiterated by stock analysts at HC Wainwright in a research report issued on Wednesday, Benzinga reports. They presently have a $92.00 target price on the stock. HC Wainwright’s price objective would indicate a potential upside of 42.97% from the company’s current price. Several […] ....

Cedric Francois , James George Chopas , Apellis Pharmaceuticals , Us Bancorp , First Horizon Advisors Inc , Stephens Consulting , Securities Exchange Commission , Jefferies Financial Group , Needham Company , News Ratings For Apellis Pharmaceuticals Daily , Analyst Recommendations For Apellis Pharmaceuticals , Apellis Pharmaceuticals Stock Down , Apellis Pharmaceuticals Inc , Wells Fargo Company , Wealth Management Inc , Covestor Ltd , Get Free Report , Financial Group , Pharmaceuticals Stock Down , Exchange Commission , George Chopas , Horizon Advisors , Apellis Pharmaceuticals Daily , Nasdaq Apls , Reiterated Rating , Hc Wainwright ,